Efficacy and Safety of Low- and High-Dose Cariprazine in Acute and Mixed Mania Associated With Bipolar I Disorder: A Double-Blind, Placebo-Controlled Study
The DOI matches its Crossref record.
Abstract
OBJECTIVE: This phase 3 trial evaluated the efficacy, safety, and tolerability of low- and high-dose cariprazine in patients meeting DSM-IV-TR criteria for acute manic or mixed episodes associated with bipolar I disorder. METHOD: This multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed/flexible-dose study was conducted from February 2010 to December 2011. Patients were randomly assigned to placebo, cariprazine 3-6 mg/d, or cariprazine 6-12 mg/d for 3 weeks of double-blind treatment. Primary and secondary efficacy parameters were change from baseline to week 3 in Young Mania Rating Scale (YMRS) total score and Clinical Global Impressions-Severity of Illness (CGI-S) score, respectively. Post hoc analysis examined change from baseline to week 3 in YMRS single items. RESULTS: A total of 497 patients were randomized; 74% completed the study. The least squares mean difference (LSMD) for change from baseline to week 3 in YMRS total score was statistically significant in favor of both cariprazine groups versus placebo (LSMD [95% CI]: 3-6 mg/d, -6.1 [-8.4 to -3.8]; 6-12 mg/d, -5.9 [-8.2, -3.6]; P < .001 [both]). Both cariprazine treatment groups showed statistically significant superiority to placebo on all 11 YMRS single items (all comparisons, P < .05). Change from baseline in CGI-S scores was statistically significantly greater in both cariprazine groups compared with placebo (LSMD [95% CI]: 3-6 mg/d, -0.6 [-0.9 to -0.4]; 6-12 mg/d, -0.6 [-0.9 to -0.3]; P < .001 [both]). The most common (≥ 5% and twice the rate of placebo) treatment-related adverse events for cariprazine were akathisia (both groups) and nausea, constipation, and tremor (6-12 mg/d only). CONCLUSIONS: Results of this study demonstrated that both low- and high-dose cariprazine were more effective than placebo in the treatment of acute manic or mixed episodes associated with bipolar I disorder. Cariprazine was generally well tolerated, although the incidence of akathisia was greater with cariprazine than with placebo. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01058668.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1713091 · Cited by 216
Durgam, S., Earley, W., Lipschitz, A., Guo, H., Laszlovszky, I., Németh, G., Vieta, E., Calabrese, J. R., & Yatham, L. N. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15020164 · Cited by 209
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“Three double-blind, placebo-controlled studies investigated the efficacy of cariprazine monotherapy in DSM-IV manic and mixed BD-I patients (Calabrese et al. 2015; Sachs et al. 2015; Durgam et al. 2015) that were also subject to a pooled analysis (Vieta et al. Mixed episode Manic mixed episode RG…”
BackgroundMethodSachs, G. S., Greenberg, W. M., Starace, A., Lu, K., Ruth, A., Laszlovszky, I., Németh, G., & Durgam, S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.018 · Cited by 127
Self-citationCitrome, L. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12752 · Cited by 107
Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder?
Fang, F., Wang, Z., Wu, R., Calabrese, J. R., & Gao, K. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1276284 · Cited by 18
Self-citationPharmacological treatment of mixed states
Cuomo, A., Nikolova, V. L., Yalin, N., Arnone, D., Fagiolini, A., & Young, A. H. (2017) · CNS Spectrums · doi:10.1017/s1092852917000013 · Cited by 14
Cutler, A. J., Laliberté, F., Germain, G., MacKnight, S. D., Boudreau, J., Wade, S. W., & Parikh, M. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2419721 · Cited by 3
“Further, owing to its broad-spectrum efficacy in treating BP-I manic or mixed and depressive episodes and generally favorable side effect profile 11,27–29 , initiating cariprazine as the first AA after BP-I diagnosis may confer important benefits for patients and for the healthcare system.”
Metadata
- Authors
- Calabrese, J. R., Keck, Jr., Starace, A., Lu, K., Ruth, A., Laszlovszky, I., Németh, G., & Durgam, S.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-11-25
- Volume
- 76
- Issue
- 03
- Pages
- 284-292
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2006478810
- Cited by
- 121
- References
- 0
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.